The X Linked Retinitis Pigmentosa GTPase Regulator pipeline drugs market research report outlays comprehensive information on the X Linked Retinitis Pigmentosa GTPase Regulator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the X Linked Retinitis Pigmentosa GTPase Regulator pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Ophthalmology which include the indications Retinitis Pigmentosa (Retinitis), and Retinal Degeneration. It also reviews key players involved in X Linked Retinitis Pigmentosa GTPase Regulator targeted therapeutics development with respective active and dormant or discontinued products.

The X Linked Retinitis Pigmentosa GTPase Regulator pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, and Preclinical stages are 2, 3, and 1 respectively.

X Linked Retinitis Pigmentosa GTPase Regulator overview

X-Linked Retinitis Pigmentosa GTPase Regulator (RPGR) is a protein encoded by the RPGR gene, and it is associated with X-linked retinitis pigmentosa (XLRP), a hereditary eye disorder leading to severe vision impairment and eventual blindness. XLRP is characterized by the degeneration of photoreceptor cells in the retina, particularly the rod cells, which are responsible for low-light vision. RPGR plays a crucial role in the normal function and maintenance of photoreceptor cells. It is primarily located in the connecting cilia of photoreceptor cells, a region critical for the transport of proteins and cellular components essential for the photoreceptor’s function. Mutations in the RPGR gene can lead to structural and functional abnormalities in the connecting cilia, disrupting the transport processes and ultimately contributing to the degeneration of photoreceptor cells.

For a complete picture of X Linked Retinitis Pigmentosa GTPase Regulator’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.